{Reference Type}: Journal Article
{Title}: Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
{Author}: Ramzy GM;Norkin M;Koessler T;Voirol L;Tihy M;Hany D;McKee T;Ris F;Buchs N;Docquier M;Toso C;Rubbia-Brandt L;Bakalli G;Guerrier S;Huelsken J;Nowak-Sliwinska P;
{Journal}: J Exp Clin Cancer Res
{Volume}: 42
{Issue}: 1
{Year}: Apr 2023 3
暂无{DOI}: 10.1186/s13046-023-02650-z
{Abstract}: <B>BACKGROUND: </B>We propose a new approach for designing personalized treatment for colorectal cancer (CRC) patients, by combining ex vivo organoid efficacy testing with mathematical modeling of the results.<BR><B>METHODS: </B>The validated phenotypic approach called Therapeutically Guided Multidrug Optimization (TGMO) was used to identify four low-dose synergistic optimized drug combinations (ODC) in 3D human CRC models of cells that are either sensitive or resistant to first-line CRC chemotherapy (FOLFOXIRI). Our findings were obtained using second order linear regression and adaptive lasso.<BR><B>RESULTS: </B>The activity of all ODCs was validated on patient-derived organoids (PDO) from cases with either primary or metastatic CRC. The CRC material was molecularly characterized using whole-exome sequencing and RNAseq. In PDO from patients with liver metastases (stage IV) identified as CMS4/CRIS-A, our ODCs consisting of regorafenib [1 mM], vemurafenib [11 mM], palbociclib [1 mM] and lapatinib [0.5 mM] inhibited cell viability up to 88%, which significantly outperforms FOLFOXIRI administered at clinical doses. Furthermore, we identified patient-specific TGMO-based ODCs that outperform the efficacy of the current chemotherapy standard of care, FOLFOXIRI.<BR><B>CONCLUSIONS: </B>Our approach allows the optimization of patient-tailored synergistic multi-drug combinations within a clinically relevant timeframe.